soul trial oral semaglutide cardiovascular outcomes results 2024 nejm 2025 Presented at ACC.25: Among participants soul trial oral semaglutide cardiovascular

While semaglutide exclusively targets GLP-1 receptors, tirzepatide simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, providing complementary metabolic effects that may enhance outcomes beyond single-pathway medications

Subcutaneous injection Subcutaneous injection remains the most common and well-studied administration route for DSIP

When dysbiosis sets in (often from antibiotics, processed foods, alcohol, mold exposure, chronic stress, or proton pump inhibitors), this estrogen handling becomes erratic, contributing to the very fluctuations that destabilize mast cells

Tamper-evident safety seals maintain product integrity during transit

However, avoid antimotility agents during the first 23 weeks unless diarrhea severely impacts daily functionallowing your gut time to adapt naturally leads to better long-term tolerance